Treatment of diabetic cardiovascular autonomic neuropathy (CAN) is a multifaceted process that includes lifestyle changes, insulin resistance reduction, optimal glycemic control, diabetic dyslipidemia management, antioxidants, vitamins, treatment of myocardial metabolic abnormalities, thrombosis, and other factors. The researchers wanted to see how simvastatin affected insulin resistance and blood lipid profile measures in patients with type 2 diabetes and the definitive stage of CAN. There were 107 patients with type 2 diabetes in the study, with 16 of them having no CAN, 19 having a subclinical stage of CAN, and 72 having confirmed CAN. Patients' median age was 53.6 0.41 years, their disease duration was 4.12 0.24 years, and their median glycated haemoglobin (HbA1c) was 7.01 percent minus 0.09 percent. The control group consisted of 14 people who were nearly healthy and did not have diabetes. Patients with definite CAN were divided into two groups for treatment: 22 patients got normal hypoglycemic medication and 20 mg of simvastatin per day in the first group; 15 individuals were in the control group. The research lasted three months. The blood glucose, HbA1c, and immunoreactive insulin (IRI) concentrations were measured. Total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglycerides (TG) concentrations were used to assess lipid metabolism. The atherogenic coefficient (AC), the TG/HDL-C parameters, and the TG-glucose (TyG) index were all calculated. There was a statistically significant increase in the parameters of HbA1c, IRI, TC, TG and HOMA-IR, AC, TyG indices and decrease of TG/HDL-C and HDL-C in patients with type 2 DM with subclinical stage of CAN compared to control; increase of IRI, TG, TG/HDL-C and TyG indices in patients with type 2 DM without CAN. Patients with a confirmed stage of cardiovascular autonomic neuropathy had the most substantial atherogenic alterations. An increase in HbA1c, IRI, TC, LDL-C levels and HOMA-IR, AC indices, as well as a considerable decrease in HDL-C concentrations, describe the definitive stage of CAN (compared to patients with subclinical CAN). As a consequence of our research, we discovered that prescribing simvastatin to patients with a confirmed stage of CAN resulted in a statistically significant drop in TC, LDL-C, and TG concentrations, as well as an increase in HDL-C content (compared to 2nd, control group). The findings support the use of statins in people with type 2 diabetes mellitus and a confirmed stage of CAN.
Author(s) Details:
Dr. Samir Ajmi,
Department of Endocrinology, Danylo
Halytsky Lviv National Medical University, 79010, Lviv, Ukraine.
Prof. Alexandr A.
Serhiyenko,
Department of Endocrinology, Danylo
Halytsky Lviv National Medical University, 79010, Lviv, Ukraine.
Victoria A.
Serhiyenko,
Department of Endocrinology, Danylo Halytsky Lviv National Medical
University, 79010, Lviv, Ukraine.
Marta E. Hotsko,
Department of Endocrinology, Danylo Halytsky Lviv National Medical
University, 79010, Lviv, Ukraine.
Please see the link here: https://stm.bookpi.org/IDMMR-V10/article/view/5814
No comments:
Post a Comment